{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T07:04:02Z","timestamp":1772953442026,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic sclerosis (SSc) is a heterogeneous autoimmune disease associated with several anti-nuclear antibodies (ANA), including those in the classification criteria (anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA Pol III). However, the presence of less common antibodies such as anti-fibrillarin (U3-RNP) that generate a clumpy nucleolar pattern by HEp-2 indirect immunofluorescence assay (IFA, ICAP AC-9) are considered disease specific and are with clinical subsets of SSc, therefore playing a role in diagnosis and prognosis. A specific and sensitive anti-fibrillarin assay would be an important addition to serological diagnosis and evaluation of SSc. The goal of this study was to evaluate a new particle-based multi-analyte technology (PMAT) for the measurement of anti-fibrillarin antibodies. A total of 149 patient samples were collected including 47 samples from France (Lyon and Paris, <jats:italic>n<\/jats:italic>\u2009=\u200932) and Italy (Careggi Hospital, Florence, <jats:italic>n<\/jats:italic>\u2009=\u200915) selected based on AC-9 HEp-2 IFA staining (&gt;\u20091:640, clumpy nucleolar pattern) and 102 non-SSc controls (inflammatory bowel disease (IBD) <jats:italic>n<\/jats:italic>\u2009=\u200920, Sj\u00f6gren\u2019s syndrome (SjS) <jats:italic>n<\/jats:italic>\u2009=\u200920, infectious disease (ID) <jats:italic>n<\/jats:italic>\u2009=\u20097, systemic lupus erythematosus (SLE) <jats:italic>n<\/jats:italic>\u2009=\u200917, rheumatoid arthritis (RA) <jats:italic>n<\/jats:italic>\u2009=\u200917, and healthy individuals (HI) <jats:italic>n<\/jats:italic>\u2009=\u200921). All samples were tested on the anti-fibrillarin PMAT assay (research use only, Inova Diagnostics, USA). Additionally, the 47 anti-fibrillarin positive samples were also tested on PMAT assays for detecting other autoantibodies in ANA-associated rheumatic diseases (AARD). Anti-fibrillarin antibody data performed by fluorescence enzyme immunoassay (FEIA, Thermo Fisher, Germany) was available for 34 samples. The anti-fibrillarin PMAT assay was positive in 31\/32 (96.9%, France) and 12\/15 (80.0%, Italy) of samples preselected based on the AC-9 IIF pattern (difference <jats:italic>p<\/jats:italic>\u2009=\u20090.09). Collectively, the PMAT assay showed 91.5% (95% confidence interval (CI): 80.1\u201396.6%) sensitivity with 100.0% (95% CI: 96.4\u2013100.0%) specificity in non-SSc controls. Strong agreement was found between PMAT and FEIA with 100.0% positive qualitative agreement (34\/34) and quantitative agreement (Spearman\u2019s rho\u2009=\u20090.89, 95% CI: 0.77.9\u20130.95%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Although most anti-fibrillarin positive samples were mono-specific (69.8%), some expressed additional antibodies (namely Scl-70, centromere, dsDNA, Ro52, Ro60, SS-B, Ribo-P, DFS70, and EJ). In conclusion, this first study on anti-fibrillarin antibodies measured using a novel PMAT assay shows promising results where the new PMAT assay had high level of agreement to FEIA for the detection of anti-fibrillarin antibodies. The availability of novel AFA assays such as PMAT might facilitate the clinical deployment, additional studies, standardization efforts, and potentially consideration of AFA for next generations of the classification criteria.<\/jats:p>","DOI":"10.1007\/s12026-021-09197-1","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T22:02:51Z","timestamp":1619647371000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies"],"prefix":"10.1007","volume":"69","author":[{"given":"Michael","family":"Mahler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrece","family":"Roup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Bentow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Fabien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boaz","family":"Palterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin J.","family":"Fritzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"issue":"1","key":"9197_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","volume":"58","author":"A Stochmal","year":"2020","unstructured":"Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"9197_CR2","doi-asserted-by":"publisher","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","volume":"19","author":"M Mahler","year":"2020","unstructured":"Mahler M, Hudson M, Bentow C, Roup F, Beretta L, Pilar Simeon C, et al. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev. 2020;19(8):102583.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"9197_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/rheumatology\/keq355","volume":"50","author":"F Galluccio","year":"2011","unstructured":"Galluccio F, Walker UA, Nihtyanova S, Moinzadeh P, Hunzelmann N, Krieg T, et al. Registries in systemic sclerosis: a worldwide experience. Rheumatology (Oxford). 2011;50(1):60\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9197_CR4","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202\u20135.","journal-title":"J Rheumatol"},{"issue":"10103","key":"9197_CR5","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"11","key":"9197_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9197_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00393-006-0065-0","volume":"65","author":"E Genth","year":"2006","unstructured":"Genth E, Krieg T. Systemic sclerosis-diagnosis and classification. Z Rheumatol. 2006;65(4):268\u201374.","journal-title":"Z Rheumatol"},{"issue":"1","key":"9197_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","volume":"37","author":"Y Hamaguchi","year":"2010","unstructured":"Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37(1):42\u201353.","journal-title":"J Dermatol"},{"issue":"2","key":"9197_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/ar628","volume":"5","author":"KT Ho","year":"2003","unstructured":"Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80\u201393.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"9197_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","volume":"12","author":"S Mehra","year":"2013","unstructured":"Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340\u201354.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"9197_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/RHU.0000000000000971","volume":"26","author":"KL Homer","year":"2020","unstructured":"Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, et al. Performance of anti-topoisomerase I antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting. J Clin Rheumatol. 2020;26(3):115\u20138.","journal-title":"J Clin Rheumatol"},{"issue":"11","key":"9197_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.autrev.2010.06.005","volume":"9","author":"M Mahler","year":"2010","unstructured":"Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality? Autoimmun Rev. 2010;9(11):756\u201360.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"9197_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/art.1780350114","volume":"35","author":"Y Okano","year":"1992","unstructured":"Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum. 1992;35(1):95\u2013100.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9197_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/sji.12510","volume":"85","author":"F Tall","year":"2017","unstructured":"Tall F, Dechomet M, Riviere S, Cottin V, Ballot E, Tiev KP, et al. The clinical relevance of antifibrillarin (anti-U3-RNP) autoantibodies in systemic sclerosis. Scand J Immunol. 2017;85(1):73\u20139.","journal-title":"Scand J Immunol"},{"key":"9197_CR15","doi-asserted-by":"crossref","unstructured":"Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum. 1996;39(7):1151\u201360.","DOI":"10.1002\/art.1780390712"},{"issue":"4","key":"9197_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.berh.2019.03.005","volume":"32","author":"ME Orme","year":"2018","unstructured":"Orme ME, Andalucia C, Sjolander S, Bossuyt X. A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: systematic literature review and meta-analysis of diagnostic test accuracy studies. Best Pract Res Clin Rheumatol. 2018;32(4):521\u201334.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"9197_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12026-015-8710-9","volume":"64","author":"LK Peterson","year":"2016","unstructured":"Peterson LK, Jaskowski TD, Mayes MD, Tebo AE. Detection of anti-U3-RNP\/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. Immunol Res. 2016;64(2):483\u20138.","journal-title":"Immunol Res"},{"issue":"7","key":"9197_CR18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9197_CR19","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.160106","volume":"43","author":"SL Nandiwada","year":"2016","unstructured":"Nandiwada SL, Peterson LK, Mayes MD, Jaskowski TD, Malmberg E, Assassi S, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol. 2016;43(10):1816\u201324.","journal-title":"J Rheumatol"},{"issue":"8","key":"9197_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3899\/jrheum.110071","volume":"38","author":"R Sharif","year":"2011","unstructured":"Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, et al. Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol. 2011;38(8):1622\u201330.","journal-title":"J Rheumatol"},{"issue":"6","key":"9197_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3899\/jrheum.160574","volume":"44","author":"C Mejia Otero","year":"2017","unstructured":"Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada YMR, Pedroza C, et al. Antifibrillarin antibodies are associated with native North American ethnicity and poorer survival in systemic sclerosis. J Rheumatol. 2017;44(6):799\u2013805.","journal-title":"J Rheumatol"},{"issue":"3","key":"9197_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66(3):740\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"9197_CR23","doi-asserted-by":"crossref","unstructured":"Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68(9):1377\u201380.","DOI":"10.1136\/ard.2008.106302"},{"issue":"Suppl 2","key":"9197_CR24","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/ar2191","volume":"9","author":"M Matucci-Cerinic","year":"2007","unstructured":"Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther. 2007;9(Suppl 2):S7.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"9197_CR25","doi-asserted-by":"publisher","first-page":"e0214202","DOI":"10.1371\/journal.pone.0214202","volume":"14","author":"PD Burbelo","year":"2019","unstructured":"Burbelo PD, Gordon SM, Waldman M, Edison JD, Little DJ, Stitt RS, et al. Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLoS ONE. 2019;14(3):e0214202.","journal-title":"PLoS ONE"},{"issue":"2","key":"9197_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","volume":"12","author":"D Villalta","year":"2012","unstructured":"Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev. 2012;12(2):114\u201320.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"9197_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/ard.2010.136929","volume":"70","author":"J Avouac","year":"2011","unstructured":"Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476\u201381.","journal-title":"Ann Rheum Dis"},{"key":"9197_CR28","doi-asserted-by":"crossref","unstructured":"Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, et al. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum. 1997;40(3):413\u20138.","DOI":"10.1002\/art.1780400304"},{"key":"9197_CR29","doi-asserted-by":"crossref","unstructured":"Richards M, Garcia-De La Torre I, Gonzalez-Bello YC, Vazquez-Del Mercado M, Andrade-Ortega L, Medrano-Ramirez G, et al. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2019;58(9):1655\u201361.","DOI":"10.1093\/rheumatology\/kez092"},{"issue":"3\/4","key":"9197_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2307\/2332926","volume":"43","author":"FJ Anscombe","year":"1956","unstructured":"Anscombe FJ. On estimating binomial response relations. Biometrika. 1956;43(3\/4):461\u20134.","journal-title":"Biometrika"},{"issue":"3\/4","key":"9197_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2307\/2332614","volume":"31","author":"JBS Haldane","year":"1940","unstructured":"Haldane JBS. the mean and variance of x2, when used as a test of homogeneity, when expectations are small. Biometrika. 1940;31(3\/4):346\u201355.","journal-title":"Biometrika"},{"issue":"167","key":"9197_CR32","first-page":"1","volume":"6","author":"C Kayser","year":"2015","unstructured":"Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6(167):1\u20135.","journal-title":"Front Immunol"},{"key":"9197_CR33","doi-asserted-by":"crossref","unstructured":"Chan EKL, Fritzler MJ, Wiik A, Andrade LEC, Reeves WH, Tincani A, et al. AutoAbSC.Org-Autoantibody Standardization Committee in 2006. Autoimmunity reviews. 2007;6(8):577\u201380.","DOI":"10.1016\/j.autrev.2007.05.001"},{"issue":"2","key":"9197_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1521-6616(03)00037-8","volume":"107","author":"M Mahler","year":"2003","unstructured":"Mahler M, Bluthner M, Pollard KM. Advances in B-cell epitope analysis of autoantigens in connective tissue diseases. Clin Immunol. 2003;107(2):65\u201379.","journal-title":"Clin Immunol"},{"issue":"10","key":"9197_CR35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","volume":"40","author":"VJ Tormey","year":"2001","unstructured":"Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford). 2001;40(10):1157\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"9197_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.181.3.1027","volume":"181","author":"KN Kasturi","year":"1995","unstructured":"Kasturi KN, Hatakeyama A, Spiera H, Bona CA. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med. 1995;181(3):1027\u201336.","journal-title":"J Exp Med"},{"key":"9197_CR37","unstructured":"Elliott S MD, Steen V. The isolated nucleolar pattern ANA antibody in a systemic sclerosis patient cohort. Poster presented at: American College of Rheumatology Convergence 2020; 2020 Nov-5\u20139; Virtual."},{"issue":"3","key":"9197_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.31138\/mjr.29.3.120","volume":"29","author":"C Liaskos","year":"2018","unstructured":"Liaskos C, Marou E, Simopoulou T, Gkoutzourelas A, Barmakoudi M, Efthymiou G, et al. Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece. Mediterr J Rheumatol. 2018;29(3):120\u20136.","journal-title":"Mediterr J Rheumatol"},{"key":"9197_CR39","unstructured":"Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, et al. To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis? Clin Exp Rheumatol. 2018;36 Suppl 113(4):109\u201317."},{"issue":"12","key":"9197_CR40","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/art.39316","volume":"67","author":"KA Patterson","year":"2015","unstructured":"Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, et al. Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis Rheumatol. 2015;67(12):3234\u201344.","journal-title":"Arthritis Rheumatol"},{"key":"9197_CR41","doi-asserted-by":"crossref","unstructured":"Mahler M, Vulsteke JB, Bossuyt X, De Langhe E, Satoh M. Standardisation of myositis-specific antibodies: where are we today? Ann Rheum Dis. 2019;0(0):1\u20133.","DOI":"10.1136\/annrheumdis-2019-216003"},{"issue":"1","key":"9197_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","volume":"9","author":"J Ronnelid","year":"2009","unstructured":"Ronnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Franck-Larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9(1):58\u201361.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"9197_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2019-216151","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"9197_CR44","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"9197_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14397595.2019.1696505","volume":"30","author":"M Kuwana","year":"2020","unstructured":"Kuwana M, Azuma A. Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol. 2020;30(2):225\u201331.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"9197_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","volume":"15","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol. 2019;15(4):208\u201324.","journal-title":"Nat Rev Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s12026-021-09206-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000}}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09197-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09197-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09197-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T08:13:47Z","timestamp":1625732027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09197-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9197"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09197-1","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"22 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12026-021-09206-3","URL":"https:\/\/doi.org\/10.1007\/s12026-021-09206-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}